» Articles » PMID: 25053986

Role of YY1 in the Pathogenesis of Prostate Cancer and Correlation with Bioinformatic Data Sets of Gene Expression

Overview
Journal Genes Cancer
Specialty Oncology
Date 2014 Jul 24
PMID 25053986
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Current treatments of various cancers include chemotherapy, radiation, surgery, immunotherapy, and combinations. However, there is a need to develop novel diagnostic and therapeutic treatments for unresponsive patients. These may be achieved by the identification of novel diagnostic and prognostic biomarkers which will help in the stratification of patients' initial responses to particular treatments and circumvent resistance, relapses, metastasis, and death. We have been investigating human prostate cancer as a model tumor. We have identified Yin Yang 1 (YY1), a dysregulated transcription factor, whose overexpression correlated with tumor progression as well as in the regulation of drug resistance and the development of EMT. YY1 expression is upregulated in human prostate cancer cell lines and tissues. We postulated that YY1 may be a potential biomarker in prostate cancer for patients' stratification as well as a novel target for therapeutic intervention. We used Bioinformatic gene RNA array datasets for the expression of YY1 in prostate tumor tissues as compared to normal tissues. Interestingly, variations on the expression levels of YY1 mRNA in prostate cancer were reported by different investigators. This mini review summarizes the current reported studies and Bioinformatic analyses on the role of YY1 in the pathogenesis of prostate cancer.

Citing Articles

Dissecting the roles and clinical potential of YY1 in the tumor microenvironment.

Li M, Wei J, Xue C, Zhou X, Chen S, Zheng L Front Oncol. 2023; 13:1122110.

PMID: 37081988 PMC: 10110844. DOI: 10.3389/fonc.2023.1122110.


LncNAP1L6 activates MMP pathway by stabilizing the m6A-modified NAP1L2 to promote malignant progression in prostate cancer.

Zheng Y, Qi F, Li L, Yu B, Cheng Y, Ge M Cancer Gene Ther. 2022; 30(1):209-218.

PMID: 36195720 PMC: 9842505. DOI: 10.1038/s41417-022-00537-3.


Protein signatures to distinguish aggressive from indolent prostate cancer.

Garcia-Marques F, Liu S, Totten S, Bermudez A, Tanimoto C, Hsu E Prostate. 2022; 82(5):605-616.

PMID: 35098564 PMC: 8916040. DOI: 10.1002/pros.24307.


Insights of RKIP-Derived Suppression of Prostate Cancer.

Dong Y, Lin X, Kapoor A, Gu Y, Xu H, Major P Cancers (Basel). 2021; 13(24).

PMID: 34945007 PMC: 8699807. DOI: 10.3390/cancers13246388.


Filtering of the Gene Signature as the Predictors of Cisplatin-Resistance in Ovarian Cancer.

Ataei A, Arab S, Zahiri J, Rajabpour A, Kletenkov K, Rizvanov A Iran J Biotechnol. 2021; 19(3):e2643.

PMID: 34825010 PMC: 8590720. DOI: 10.30498/ijb.2021.209370.2643.


References
1.
Tennakoon J, Shi Y, Han J, Tsouko E, White M, Burns A . Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. Oncogene. 2013; 33(45):5251-61. PMC: 4009392. DOI: 10.1038/onc.2013.463. View

2.
Latulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V . Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002; 62(15):4499-506. View

3.
Gill G, Ptashne M . Negative effect of the transcriptional activator GAL4. Nature. 1988; 334(6184):721-4. DOI: 10.1038/334721a0. View

4.
Baritaki S, Yeung K, Palladino M, Berenson J, Bonavida B . Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res. 2009; 69(21):8376-85. DOI: 10.1158/0008-5472.CAN-09-1069. View

5.
Denz A, Pilarsky C, Muth D, Ruckert F, Saeger H, Grutzmann R . Inhibition of MIF leads to cell cycle arrest and apoptosis in pancreatic cancer cells. J Surg Res. 2009; 160(1):29-34. DOI: 10.1016/j.jss.2009.03.048. View